Open AccessRATIONAL PHARMACOTHERAPY OF CHRONIC URTICARIA
Author(s) -
Е Е Некрасова,
А. В. Пономарева,
Т Г Федоскова
Publication year - 2013
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja654
Subject(s) - cetirizine , medicine , antihistamine , levocetirizine , drug , pharmacology
The aim of this study was to reveal most clinically effective and economically expedient anti-H1-receptor antagonist cetirizine generation (original or generic), to carry out the analysis of pharmaceutical equivalence of cetirizine generation anti-H-receptor antagonists manufactured by different companies. Materials and methods. Study is executed in design of simple open comparative prospective randomized research in parallel groups. The preliminary analysis of volume and structure of H-antihistamine cetirizine generation products retails for the purpose of definition of the most widespread trademarks was carried out 117 patients with chronic idiopathic urticaria (CIU) treated with various trademarks cetirizine 10 mg/day within 4 weeks were included in the study. Clinical efficiency criteria: dynamics of urticaria symptoms, change of index severity, remission period, days free from CIU symptoms. The pharmaceutical analysis included comparative studying of rate of dissolution and quantitative identification of medicinal substance. The pharmacoeconomic analysis was done by an «expense-efficiency» method. Results. All investigated drugs of cetirizine in a dose of 10 mg dayly significantly (p Cetirizine-Hexal > Zodak.